文献速递肺栓塞与肺血管病

低风险肺动脉高压患者是否真正从初始联合治疗中获益?AMBITION试验的启示

Do Patients With Low-Risk Pulmonary Arterial Hypertension Really Benefit From Upfront Combination Therapy?: Insight From the AMBITION Trial.
PubMed 文献 · Chest · 2023-06-24

该研究基于AMBITION试验数据,用REVEAL 2.0评分和PHORA工具将肺动脉高压患者分为低、中、高风险。结果显示,低风险患者接受初始联合治疗在临床恶化时间上无统计学显著获益,且副作用发生率更高但不显著;中高风险患者则显著获益。提示低风险患者或许需进一步分层后再决定初始联合治疗。

要点

  • 低风险PAH患者初始联合治疗未显著改善临床恶化时间。
  • 低风险患者联合治疗副作用发生率更高但不显著。
  • 中高风险PAH患者初始联合治疗显著获益。

核心结论

  • 低风险PAH患者按REVEAL 2.0或PHORA分类时,初始联合治疗在临床恶化时间上无统计学显著获益。
  • 低风险PAH患者接受初始联合治疗的副作用发生率更高但不显著。
  • 中高风险PAH患者初始联合治疗在各项终点上均显著获益。

研究设计与样本

  • 基于AMBITION试验数据的回顾性分析,使用REVEAL 2.0评分和PHORA工具将PAH患者分为低、中、高风险。
  • 主要终点为临床恶化时间(包括死亡、PAH恶化住院和疾病进展),在入组后1年和3年截尾。

主要发现

  • 低风险PAH(REVEAL 2.0分类)考虑临床恶化或副作用时3年HR为0.75(95%CI 0.39-1.47;P=0.4)。
  • 中高风险PAH患者初始联合治疗在各项终点上均显示统计学显著获益。

临床怎么用

  • 对低风险PAH患者,在决定初始联合治疗前可考虑使用其他方法进一步风险分层。
  • 临床决策时应权衡初始联合治疗在低风险患者中的副作用风险。

局限性

  • 本研究为基于AMBITION试验数据的分析,结果需前瞻性数据验证。
  • 在改变当前指南导向治疗前,需进一步研究确认。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Based on results of the Ambrisentan and Tadalafil in Patients with Pulmonary Arterial Hypertension (AMBITION) trial, upfront combination therapy is recommended for treatment-naive patients with low-risk pulmonary arterial hypertension (PAH). However, conflicting data exist whether adopting this treatment strategy in this risk group is beneficial or well tolerated. RESEARCH QUESTION: Do patients with low-risk PAH really benefit from upfront combination therapy? STUDY DESIGN AND METHODS: Using the data from the original AMBITION trial, patients with PAH were classified as low, intermediate, or high risk using the Registry to Evaluate Early and Long-term PAH Disease Management 2.0 (REVEAL 2.0) score and the Pulmonary Hypertension Outcomes and Risk Assessment (PHORA) tool. The primary end point was time to clinical worsening (including death, hospitalization for PAH worsening, and disease progression) censored at 1- and 3-year post-enrollment. Side effects that led to withdrawal of treatment were also considered. RESULTS: Patients with low-risk PAH categorized by REVEAL 2.0 and PHORA did not see a statistically significant benefit of upfront combination therapy vs monotherapy for time to clinical worsening at 1 and 3 years' post-enrollment using Cox proportional analysis (3-year hazard ratio of 0.40 [95% CI, 0.15-1.06; P = .07] and 0.55 [95% CI, 0.26-1.18; P = .12] for REVEAL 2.0 and PHORA, respectively) or considering time to clinical worsening or side effects (3-year hazard ratio of 0.75 [95% CI, 0.39-1.47; P = .4] and 0.87 [95% CI, 0.49-1.54; P = .63] for REVEAL 2.0 and PHORA). Patients with low-risk PAH on upfront combination therapy experienced a higher but not significant incidence of side effects using REVEAL 2.0 and PHORA. In contrast, patients at intermediate or high risk saw a statistically significant benefit of upfront combination therapy considering each of the end points regardless of side effects. INTERPRETATION: This analysis suggests that perhaps some patients with low-risk PAH should be further stratified using other modalities prior to committing to upfront combination therapy, especially when the occurrence of side effects is considered. Further prospective data are needed to validate this hypothesis prior to changes in current guideline directed therapy are contemplated.

来源:Chest,查看原文。版权归原作者所有。

引用

  1. Fauvel C, Liu Y, Correa-Jaque P, et al. Do Patients With Low-Risk Pulmonary Arterial Hypertension Really Benefit From Upfront Combination Therapy?: Insight From the AMBITION Trial. Chest. 2023. PMID: 37356711. doi:10.1016/j.chest.2023.06.023

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。